Stockscreener 앱 받기
14.03
3.17%
-0.46
전일 마감가:
$14.49
열려 있는:
$14
하루 거래량:
1,612
Relative Volume:
0.30
시가총액:
$36.72M
수익:
$5.02M
순이익/손실:
$-18.31M
주가수익비율:
-3.0971
EPS:
-4.53
순현금흐름:
$-23.40M
1주 성능:
-4.02%
1개월 성능:
-17.52%
6개월 성능:
-33.82%
1년 성능:
+6.45%
1일 변동 폭
$14.00
$14.03
1주일 범위
$14.00
$15.68
52주 변동 폭
$12.58
$26.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
명칭
Vtv Therapeutics Inc
전화
336-841-0300
주소
3980 PREMIER DR, HIGH POINT, NC
VTVT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
14.03 | 37.92M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-05-30 | 개시 | H.C. Wainwright | Buy |
| 2018-04-10 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 개시 | Northland Capital | Outperform |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2015-09-04 | 개시 | Canaccord Genuity | Buy |
| 2015-08-24 | 개시 | Piper Jaffray | Overweight |
| 2015-08-24 | 개시 | Stifel | Buy |
모두보기
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
vTv Therapeutics Inc. stock retracement – recovery analysisSell Signal & Verified Stock Trade Ideas - Newser
What earnings revisions data tells us about vTv Therapeutics Inc.July 2025 Update & Accurate Technical Buy Alerts - Newser
VTv Therapeutics Q2 Financial Results: $6M LossNews and Statistics - IndexBox
VTv Therapeutics: Q2 Earnings Snapshot - Connecticut Post
vTv Therapeutics Reports Q2 2025 Financials, Advances Cadisegliatin Trials, and Appoints New CFO - AInvest
Is vTv Therapeutics Inc. trending in predictive chart models [Quarterly Profit Review]Short-Term Trading Alerts - Newser
How to monitor vTv Therapeutics Inc. with trend dashboardsFree Alpha Driven Watchlist With Alerts - Newser
vTv Therapeutics Inc. Stock Support and Resistance Levels You Should Know [Gold Moves]Safe Entry Zone Tips - Newser
vTv Therapeutics and the Potential of Cadisegliatin in Transforming Type 1 Diabetes Management - AInvest
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | VTVT Stock News - GuruFocus
vTv Therapeutics Reports Q2 2025 Results, Phase 3 CATT1 Trial Begins - AInvest
vTv Therapeutics Reports First Participant Randomized in Phase 3 CATT1 Trial for Cadisegliatin and Expands Intellectual Property Portfolio - Quiver Quantitative
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Novel Oral Diabetes Drug Enters Phase 3 Trial: vTv's Potential First-in-Class Treatment Advances - Stock Titan
Is vTv Therapeutics Inc. trending in predictive chart modelsAI Screener Based Stock Summary Report - Newser
Using fundamentals and technicals on vTv Therapeutics Inc.ROI Prediction from Long-Term Holding Plans - Newser
What makes vTv Therapeutics Inc. stock price move sharplySummary of Long-Term Buy Zone Stocks - Newser
vTv Therapeutics VTVT Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Using data models to predict vTv Therapeutics Inc. stock movementChart Confirmation Setup with ROI Signals - Newser
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin | VTVT Stock News - GuruFocus
What machine learning models say about vTv Therapeutics Inc.Free Low Capital High Return Stock Plans - Newser
vTv Therapeutics Receives Notice of Allowance for Cadisegliatin Patent, Strengthening Protection for Type 1 Diabetes Treatment - Quiver Quantitative
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - GlobeNewswire
vTv Secures 20-Year Patent Protection for First-in-Class Type 1 Diabetes Drug Cadisegliatin - Stock Titan
Does vTv Therapeutics Inc. fit your quant trading modelFree Growth Focused Entry Plan Suggestions - Newser
Relative strength of vTv Therapeutics Inc. in sector analysisSwing Watchlist With Tight Stop Placement - Newser
What MACD and RSI say about vTv Therapeutics Inc.Short-Term Trade Setup with Forecast Insight - Newser
What’s next for vTv Therapeutics Inc. stock priceShort Term Momentum Based Trading Strategy - Newser
Custom strategy builders for tracking vTv Therapeutics Inc.Free Secure Capital Picks With Upside Potential - Newser
Why vTv Therapeutics Inc. stock attracts strong analyst attentionAI Triggered Buy Zone Forecast System - Newser
Should I buy vTv Therapeutics Inc. stock before earningsFree Access to Real-Time Trade Insights - Newser
How Resilient Is vTv Therapeutics Inc. Stock During Economic DownturnsFree Trade Setups With AI Powered Filters - Newser
vTv Therapeutics announces first participant randomized in CATT1 Phase 3 trial - TipRanks
vTv Therapeutics begins phase 3 trial for type 1 diabetes oral therapy - Investing.com
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - The Manila Times
vTv Therapeutics Announces First Study Participant - GlobeNewswire
Advanced analytics toolkit walkthrough for vTv Therapeutics Inc.Chart Driven Opportunity Scanner with Alerts - Newser
First-Ever Oral Type 1 Diabetes Drug Enters Phase 3 TrialFDA Breakthrough Status Could Transform Treatment - Stock Titan
vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Thursday - Defense World
vTv Therapeutics Inc. stock daily chart insightsFree Community Verified Stock Suggestions - Newser
Moving Average Crossover Confirms Uptrend in vTv Therapeutics Inc.Momentum Based Equity Trading Plans Reviewed - beatles.ru
Vtv Therapeutics Inc (VTVT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.67%
자본화:
|
볼륨(24시간):